---
title: "Xizang Weixinkang Pharmaceutical: Cooperative product injectable multivitamins (12) passed the consistency evaluation of generic drugs"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/245845561.md"
description: "Xizang Weixinkang Pharmaceutical announced that its cooperative manufacturer Pude Pharmaceutical has received the drug supplementary application notice approved by the National Medical Products Administration for injectable multivitamins (12), which has passed the consistency evaluation of quality and efficacy for generic drugs. Injectable multivitamins (12) are the company's core products, suitable for adult patients and children over 11 years old who require intravenous vitamin supplementation"
datetime: "2025-06-24T08:38:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/245845561.md)
  - [en](https://longbridge.com/en/news/245845561.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/245845561.md)
generator: "portal-rs"
---

# Xizang Weixinkang Pharmaceutical: Cooperative product injectable multivitamins (12) passed the consistency evaluation of generic drugs

According to the announcement from Weixinkang (603676.SH), the company's cooperative production partner, Shanxi Pude Pharmaceutical Co., Ltd. (referred to as "Pude Pharmaceutical"), has recently received the approval notice for the supplementary application of injectable multivitamins (12) issued by the National Medical Products Administration. This drug has passed the consistency evaluation of quality and efficacy for generic drugs. Injectable multivitamins (12) are independently developed by the company, with Pude Pharmaceutical responsible for drug registration and production, making it a core product of the company.

Injectable multivitamins (12) are used for intravenous vitamin supplementation and are suitable for adults and children over 11 years old who cannot or have insufficient oral nutrition (malnutrition, poor absorption, parenteral nutrition, etc.) and need to supplement vitamins through injection

### Related Stocks

- [603676.CN](https://longbridge.com/en/quote/603676.CN.md)

## Related News & Research

- [05:00 ETNorroy Bioscience Initiates Pivotal Phase III Clinical Trial of 177Lu-NYM032, a PSMA-Targeted Radioligand Therapy for mCRPC](https://longbridge.com/en/news/297758164.md)
- [Unigold says Dominican community backs ESIA launch for Neita gold project](https://longbridge.com/en/news/297646851.md)
- [Geiger Makes New Uranium Discovery at the Previously Undrilled Fox Zone, Directly on Trend with Orano's Kiggavik Uranium Deposits | BSENF Stock News](https://longbridge.com/en/news/297633664.md)
- [TKMS says F127 air-defense frigate design advances after customer-driven development work](https://longbridge.com/en/news/297673767.md)
- [06:05 ETKarmanos Now Offers FDA-Approved Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer](https://longbridge.com/en/news/297497971.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**